Posts by Mike Mooney
Empower a Future Free of FTD with a Year-End Gift
For over 20 years, AFTD’s volunteers, supporters, and partners raised awareness, supported one another, educated healthcare professionals, advanced research, and advocated for a better tomorrow. When you support AFTD’s mission,…
Read MoreAFTD Research Team: A Year in Review
2024 has been a hopeful year for FTD Research, and it’s also been an exciting year for the AFTD research team. It isn’t easy to summarize all that’s been accomplished…
Read MoreArticle Lists Ways Researchers Can Involve People with Dementia in Identifying Research Priorities
A research article published in the Journal of the American Geriatrics Society discusses how researchers can better involve people living with FTD and other types of dementia in discussions to…
Read MoreAdvancing Hope: AFTD Attends 2024 Society for Neuroscience Meeting
Dr. Nicole Bjorklund, AFTD Director of Research and Grants, and Dr. Kate Still, Research Outreach Manager, attended the Society for Neuroscience meeting in October to take in the latest research…
Read MoreTransposon Presents Results from Successful Phase 2 ALS/FTD Clinical Trial
Biotechnology company Transposon Therapeutics presented the results from its successful phase 2 clinical trial of its experimental medication for ALS/FTD at the 35th International Symposium on ALS/MND. The trial of…
Read MoreDear HelpLine: Types of FTD
Dear HelpLine, My mom was recently diagnosed with FTD, and when I visited your website, I learned that there are several types of FTD. My mom wasn’t diagnosed with a…
Read MoreAdvancing Hope: AFTD Develops New Gene Therapy Resource
There is more hope now than ever before that researchers will be able to develop a treatment for FTD. Much research is underway to understand FTD better, treat the symptoms,…
Read MoreEmpower Help & Hope this #Giving Tuesday
Michele Howerter, whose mom Nancy is living with primary progressive aphasia, is sharing her family’s story for Giving Tuesday – a day to recognize and support mission-focused organizations worldwide. AFTD…
Read MoreAdvancing Hope: Sponsored Testing Programs; opportunities for no-cost genetic testing
Once you have chosen to pursue genetic testing, it can be frustrating to learn that the cost is too high, or insurance will not cover genetic testing. Sponsored testing programs…
Read MoreFerrer Doses First Participant in Phase 2 Study for PSP Treatment
Pharmaceutical company Ferrer announced that it has dosed the first participant in the PROSPER phase 2 clinical trial for an experimental treatment for progressive supranuclear palsy. The ongoing trial seeks…
Read More
English 
Spanish (Mexico) 
French 
German 
Swedish 
Portuguese 
Italian 
Dutch 
Danish 
Polish 
Spanish (Spain)